134 related articles for article (PubMed ID: 25927583)
1. A Fusion Protein of RGD4C and β-Lactamase Has a Favorable Targeting Effect in Its Use in Antibody Directed Enzyme Prodrug Therapy.
Wang H; Zhou XL; Long W; Liu JJ; Fan FY
Int J Mol Sci; 2015 Apr; 16(5):9625-34. PubMed ID: 25927583
[TBL] [Abstract][Full Text] [Related]
2. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
3. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a fusion protein of RGD4C and the β-lactamase variant for antibody-directed enzyme prodrug therapy.
Zhou X; Wang H; Shi P; Meng AM
Onco Targets Ther; 2014; 7():535-41. PubMed ID: 24748803
[TBL] [Abstract][Full Text] [Related]
5. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).
Alderson RF; Toki BE; Roberge M; Geng W; Basler J; Chin R; Liu A; Ueda R; Hodges D; Escandon E; Chen T; Kanavarioti T; Babé L; Senter PD; Fox JA; Schellenberger V
Bioconjug Chem; 2006; 17(2):410-8. PubMed ID: 16536473
[TBL] [Abstract][Full Text] [Related]
7. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy.
Harding FA; Liu AD; Stickler M; Razo OJ; Chin R; Faravashi N; Viola W; Graycar T; Yeung VP; Aehle W; Meijer D; Wong S; Rashid MH; Valdes AM; Schellenberger V
Mol Cancer Ther; 2005 Nov; 4(11):1791-800. PubMed ID: 16276001
[TBL] [Abstract][Full Text] [Related]
8. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT.
Roberge M; Estabrook M; Basler J; Chin R; Gualfetti P; Liu A; Wong SB; Rashid MH; Graycar T; Babé L; Schellenberger V
Protein Eng Des Sel; 2006 Apr; 19(4):141-5. PubMed ID: 16436454
[TBL] [Abstract][Full Text] [Related]
9. Construction, expression and functional characterization of the β-lactamase with αv integrin ligands.
Wang H; Shi PJ; Wu MF; Li N; Zhou XL; Fan FY
Protein Pept Lett; 2010 Dec; 17(12):1562-5. PubMed ID: 20858201
[TBL] [Abstract][Full Text] [Related]
10. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
11. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
12. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
13. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
Sharma SK; Bagshawe KD
Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
15. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
17. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Bagshawe KD; Sharma SK; Begent RH
Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
[TBL] [Abstract][Full Text] [Related]
18. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Rodrigues ML; Carter P; Wirth C; Mullins S; Lee A; Blackburn BK
Chem Biol; 1995 Apr; 2(4):223-7. PubMed ID: 9383424
[TBL] [Abstract][Full Text] [Related]
20. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
